A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...
GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a ...
A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...
GSK (GSK) is reportedly suing Pfizer (PFE) and partner BioNTech (BNTX) for patent infringement over the use of certain mRNA ...
GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 ...
Q4 2023 Earnings Call April 24, 2024 CureVac N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Vaccines Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global COVID-19 Vaccines Market to Reach 4.2 Billion Doses by 2025 The global market ...
CureVac continues to advance its clinical development programs in prophylactic vaccines in collaboration with GSK. All currently tested candidates apply modified mRNA and are based on CureVac’s ...
Mass gatherings can attract several million people from across the world and pose huge public health challenges for the host ...
COVID vaccine booster shots were rolled out, and about 40 percent of US adults said they did not plan on getting a booster.
People who got the COVID-19 booster had stronger protection against the virus that causes the disease compared to people who ...